Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Dimed Distribuidora de Medicamentos Forward PE Ratio Related Terms
Dimed Distribuidora de Medicamentos Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos Forward PE Ratio Chart
Dimed Distribuidora de Medicamentos Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
7.50
8.25
Dimed Distribuidora de Medicamentos Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
7.50
7.65
8.21
6.84
8.25
10.12
BSP:PNVL3 vs LLY, JNJ, ABBV: Forward PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's Forward PE Ratio falls into.
Dimed Distribuidora de Medicamentos Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a Forward PE Ratio of 8.42 as of Aug. 04, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Dimed Distribuidora de Medicamentos and its competitors. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #59 out of 409 companies in the Drug Manufacturers industry, placing it in the top 14.4%.
Is Dimed Distribuidora de Medicamentos' Forward PE Ratio too high?
Dimed Distribuidora de Medicamentos' current Forward PE Ratio is 8.42. The Drug Manufacturers industry median Forward PE Ratio is 17.47. Dimed Distribuidora de Medicamentos' value of 8.42 is 51.8% below this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #59 out of 409 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' Forward PE Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #59 out of 409 companies for Forward PE Ratio. This places Dimed Distribuidora de Medicamentos in the top 14% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 17.47. Dimed Distribuidora de Medicamentos' value of 8.42 is 51.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.47, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current Forward PE Ratio of 8.42 is 51.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Dimed Distribuidora de Medicamentos and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current Forward PE Ratio is 8.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.84, compared to a current price of R$11.93 — trading 13.8% below its estimated fair value. The current Forward PE Ratio is 8.42 and 51.8% below the Drug Manufacturers industry median of 17.47. Dimed Distribuidora de Medicamentos' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current Forward PE Ratio is 8.42 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued.
The current stock price of R$11.93 is trading 13.8% below its estimated GF Value™ of R$13.84.
GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.
Key valuation signals for BSP:PNVL3:
Forward PE Ratio: 8.42
GF Value™: R$13.84 vs. price of R$11.93 (13.8% below fair value)
Industry Position: 51.8% below the Drug Manufacturers median (#59 of 409)
No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
88GF Score
Get the complete analysis for BSP:PNVL3
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PNVL3 has been successfully added to your 
